Drug Profile
Methyl beta cyclodextrin - SolAeroMed
Alternative Names: Methyl-β-cyclodextrin - SolAeroMed; MβCD - SolAeroMed; Research programme: methyl-beta-cyclodextrin - SolAeroMed; S-1229Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator SolAeroMed
- Class Antibronchitics; Antifibrotics; Cyclodextrins
- Mechanism of Action Surface active agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute lung injury; Adult respiratory distress syndrome; Bronchiectasis; Cystic fibrosis; Idiopathic pulmonary fibrosis
Most Recent Events
- 25 Apr 2023 Preclinical development for Acute lung injury and Adult respiratory distress syndrome is ongoing in Canada (Inhalation, Aerosol) (SolAeroMed pipeline, April 2023)
- 24 Mar 2023 Preclinical trials in Bronchiectasis in Canada (Inhalation) (Solaeromed pipeline, March 2023)
- 24 Mar 2023 Preclinical trials in Cystic fibrosis in Canada (Inhalation) (Solaeromed pipeline, March 2023)